Sanofi sharpens focus on bispecifics, and China, with Alphamab deal
It’s not the splashy acquisition Sanofi was expected to make after pocketing more than $11 billion following the sale of a big chunk of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
